Booking Holdings Inc (BKNG) Stock Price Today
Key Stats
- $149.59BMarket Cap
- -Volume
- Consumer CyclicalSector
- $223.4352W High
- $154.1352W Low
- -Typical Hold Time
- $153.07BEnterprise Value
- 0.84%Div Yield
- -Trading Activity
Track Booking Holdings Inc (BKNG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Booking Holdings Inc has traded between a low of $154.13 and a high of $223.43, highlighting its annual price range. Buy and sell Booking Holdings Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Most Recent News
Alphabet struggles to build AI capacity fast enough; Anthropic secures 5 gigawatts of AI power.
Alphabet CEO Sundar Pichai revealed that the company is facing challenges in rapidly expanding its AI capacity to meet demand. Meanwhile, competitor Anthropic has successfully secured 5 gigawatts of AI computing power, highlighting a significant deve...
Aclara advances rare earths strategy with $1.66B NPV Carina project, facing financing and execution risks.
Aclara is progressing its heavy rare earths strategy by integrating the Carina mining project and a U.S. separation facility to capture more downstream margins. The Carina feasibility study shows a strong after-tax net present value (NPV) of $1.66 bi...
Shattuck Labs shifts to immunology with promising SL-325 for IBD, showing strong safety and potential quarterly dosing.
Shattuck Labs has pivoted from oncology to focus on immunology, specifically developing DR3-targeted therapies for inflammatory bowel disease (IBD). Their lead candidate, SL-325, demonstrated strong safety, low immunogenicity, and durable receptor oc...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.